abrdn plc Purchases New Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)

abrdn plc acquired a new stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) in the fourth quarter, according to its most recent filing with the SEC. The fund acquired 25,803 shares of the company’s stock, valued at approximately $608,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. China Universal Asset Management Co. Ltd. boosted its position in shares of Dyne Therapeutics by 11.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 21,575 shares of the company’s stock valued at $508,000 after acquiring an additional 2,265 shares during the period. KBC Group NV boosted its holdings in Dyne Therapeutics by 45.3% in the 4th quarter. KBC Group NV now owns 3,135 shares of the company’s stock valued at $74,000 after purchasing an additional 978 shares during the period. JPMorgan Chase & Co. grew its position in shares of Dyne Therapeutics by 4.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 101,750 shares of the company’s stock valued at $3,655,000 after purchasing an additional 4,236 shares in the last quarter. Virtue Capital Management LLC grew its position in shares of Dyne Therapeutics by 4.4% during the 3rd quarter. Virtue Capital Management LLC now owns 23,208 shares of the company’s stock valued at $834,000 after purchasing an additional 981 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Dyne Therapeutics by 4.8% in the third quarter. Geode Capital Management LLC now owns 1,859,413 shares of the company’s stock worth $66,802,000 after purchasing an additional 84,760 shares during the period. Institutional investors own 96.68% of the company’s stock.

Insider Buying and Selling at Dyne Therapeutics

In other Dyne Therapeutics news, Director Carlo Incerti sold 16,500 shares of the company’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $28.73, for a total transaction of $474,045.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Richard William Scalzo sold 1,455 shares of the business’s stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total transaction of $40,914.60. Following the transaction, the senior vice president now directly owns 127,078 shares of the company’s stock, valued at $3,573,433.36. The trade was a 1.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 21,071 shares of company stock worth $606,476. 20.77% of the stock is owned by corporate insiders.

Analyst Ratings Changes

DYN has been the subject of a number of research reports. Royal Bank of Canada reissued an “outperform” rating and issued a $45.00 price target on shares of Dyne Therapeutics in a research note on Tuesday, January 14th. Guggenheim reiterated a “buy” rating on shares of Dyne Therapeutics in a research report on Friday, January 24th. Robert W. Baird assumed coverage on Dyne Therapeutics in a research report on Friday, December 13th. They set an “outperform” rating and a $46.00 price target on the stock. Baird R W upgraded Dyne Therapeutics to a “strong-buy” rating in a report on Thursday, December 12th. Finally, Chardan Capital reissued a “buy” rating and set a $50.00 price objective on shares of Dyne Therapeutics in a report on Friday, January 10th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $49.91.

Dyne Therapeutics Price Performance

NASDAQ:DYN opened at $13.52 on Wednesday. The firm’s 50-day moving average price is $20.35 and its 200-day moving average price is $30.15. The company has a market capitalization of $1.38 billion, a PE ratio of -3.80 and a beta of 1.11. Dyne Therapeutics, Inc. has a 1-year low of $13.23 and a 1-year high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). Equities analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.